This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection.

##STR00001## wherein: X is C or N with the proviso that when X is N, R.sup.1 does not exist; W is C or N with the proviso that when W is N, R.sup.2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of

##STR00002##

Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I.

##STR00003## wherein: L and M are independently selected from the group consisting of C.sub.1-C.sub.6 alkyl, phenyl, benzyl, trialkylsilyl, 2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

A cross-linkable flame retardant material includes a terminal furan-containing flame retardant moiety. The terminal furan-containing flame retardant moiety includes a furan moiety bonded to a phosphorus moiety via a phosphoryl linkage or via a phosphinyl linkage.

Described herein is a process for antibiotic development comprising: (a) generating a compound of formula (III):

##STR00001##

or a salt or stereoisomer or prodrug thereof; wherein R.sup.1-R.sup.3 and R.sup.5-R.sup.10 are independently selected from H, alkyl group, substituted alkyl group, halogen, OH, NH.sub.2, or SH; R.sup.4 is H, alkyl group or substituted alkyl group; X.sup.1-X.sup.2 are independently selected from O, S, NH, H, alkyl, halogen, OH, SH, or NH.sub.2; W is a saturated acyclic hydrocarbon chain of 1 to 15 carbon atoms; and Z is a neutral or positively charged organic group comprising a nitrogen or phosphorus atom; and; and (b) determining efficacy of the compound to inhibit growth of a bacteria. Systems of drug development of these antibiotic compounds are also described.

Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof for sequencing a nucleic acid.

Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof for sequencing a nucleic acid.

An additive for a non-aqueous electrolyte solution that can suppress the initial gas generation amount when used in a non-aqueous electrolyte solution battery. The additive for a non-aqueous electrolyte solution is represented by any one of formulae [1] to [4]:

##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.1, X.sup.2 and Y are as defined in the specification.

This document relates to functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such functionalized polymers.

Enolase levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of hypoxia-activated achiral phosphoramide mustards.

A process of forming a resveratrol-based flame retardant small molecule with a phosphonate/phosphinate molecule that includes a chloride group and a terminal functional group.

A simple preparation method for a dialkoxypropyl methylphosphonate, wherein a methyl halogenated phosphonate monoester is reacted with a 3,3-dialkoxypropyl magnesium or zinc halide to obtain a 3,3-dialkoxypropyl methylphosphonate. The starting materials are readily available, the operations are simple, the conditions are mild, the synthesis conversion rate is high, and the method is suitable for industrial production.